Skip to main content
. 2020 Dec 1;10:20922. doi: 10.1038/s41598-020-77515-y

Table 2.

Incidence of HCC in UMHS and PUHSC cohorts before and after SVR (SVR as a time-dependent variable).

UMHS cohort PUHSC cohort Total HR (95% CI) P value
Patients at risk Patients developed HCC HCC incidence (per 100 person-year) Patients at risk Patients developed HCC HCC incidence (per 100 person-year) Patients at risk Patients developed HCC HCC incidence (per 100 person-year)
No cirrhosis group
Before SVR 434 8 0.7 (0.3–1.4) 716 2 0.1 (0.02–0.3) 1150 10 0.3 (0.1–0.5)
After SVR 294 0 NA 385 0 NA 679 0 NA NA
Total 434 8 0.6 (0.3–1.1) 716 2 0.1 (0.02–0.3) 1150 10 0.2 (0.1–0.4)
Cirrhosis group
Before SVR 361 30 3.4 (2.4–4.9) 138 10 2.5 (1.3–4.7) 499 40 3.1 (2.3–4.3) 1.0
After SVR 164 7 2.9 (1.4–6.0) 59 1 1.6 (0.2–11.5) 223 8 2.6 (1.3–5.2) 0.9 (0.4–1.9) 0.74
Total 361 37 3.3 (2.4–4.5) 138 11 2.4 (1.3–4.3) 499 48 3.0 (2.3–4.0)
Overall
Before SVR 795 38 1.9 (1.4–2.6) 854 12 0.4 (0.2–0.7) 1649 50 1.0 (0.8–1.3) 1.0
After SVR 458 7 1.4 (0. 7–2.9) 444 1 0.2 (0.03–1.6) 902 8 0.8 (0.4–1.7) 0.8 (0.4–1.6) 0.53
Total 795 45 1.8 (1.3–2.4) 854 13 0.4 (0.2–0.7) 1649 58 1.0 (0.8–1.3)

HCC Hepatocellular carcinoma, SVR sustained virologic response, HR hazard ratio, NA not applicable.